A detailed history of Sg Americas Securities, LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 57,566 shares of LYEL stock, worth $63,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
57,566
Previous 32,319 78.12%
Holding current value
$63,322
Previous $47,000 68.09%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$1.13 - $1.88 $28,529 - $47,464
25,247 Added 78.12%
57,566 $79,000
Q2 2024

Jul 12, 2024

SELL
$1.3 - $3.01 $46,729 - $108,197
-35,946 Reduced 52.66%
32,319 $47,000
Q1 2024

May 06, 2024

SELL
$1.71 - $3.07 $52,934 - $95,034
-30,956 Reduced 31.2%
68,265 $152,000
Q4 2023

Jan 12, 2024

BUY
$1.39 - $2.35 $62,113 - $105,012
44,686 Added 81.94%
99,221 $192,000
Q3 2023

Oct 13, 2023

BUY
$1.45 - $3.35 $79,075 - $182,692
54,535 New
54,535 $80,000
Q1 2023

Apr 28, 2023

BUY
$1.97 - $3.58 $12,738 - $23,148
6,466 Added 10.52%
67,953 $160,000
Q4 2022

Feb 02, 2023

BUY
$2.78 - $8.09 $40,629 - $118,235
14,615 Added 31.18%
61,487 $213,000
Q3 2022

Oct 31, 2022

SELL
$5.54 - $8.27 $225,206 - $336,183
-40,651 Reduced 46.45%
46,872 $344,000
Q2 2022

Jul 29, 2022

BUY
$3.68 - $6.8 $31,007 - $57,296
8,426 Added 10.65%
87,523 $571,000
Q1 2022

Apr 29, 2022

BUY
$5.05 - $7.7 $399,439 - $609,046
79,097 New
79,097 $399,000
Q4 2021

Feb 07, 2022

SELL
$7.13 - $15.19 $75,763 - $161,408
-10,626 Closed
0 $0
Q3 2021

Nov 01, 2021

BUY
$11.0 - $17.95 $116,886 - $190,736
10,626 New
10,626 $157,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.